This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Ephrin receptor
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='3fxx' size=' | + | <StructureSection load='3fxx' size='350' side='right' scene='45/450911/Cv/1' caption='Human ephrin A3 receptor (magenta) complex with peptide substrate (green), nucleotide derivative and Mg+2 ion [[3fxx]]'> |
== Function == | == Function == | ||
| Line 27: | Line 27: | ||
**[[3kka]] - hEPHR A1 SAM+ hEPH A2 SAM – human<BR /> | **[[3kka]] - hEPHR A1 SAM+ hEPH A2 SAM – human<BR /> | ||
**[[3hil]] - hEPHR A1 SAM<br /> | **[[3hil]] - hEPHR A1 SAM<br /> | ||
| - | **[[ | + | **[[2k1k]] - hEPHR A1 transmembrane domain – NMR<BR /> |
**[[1x5a]] - hEPHR A1 fn3 domain – NMR<BR /> | **[[1x5a]] - hEPHR A1 fn3 domain – NMR<BR /> | ||
*Ephrin A2 receptor | *Ephrin A2 receptor | ||
| Line 33: | Line 33: | ||
**[[2x10]], [[3fl7]] - hEPHR A2 ectodomain<BR /> | **[[2x10]], [[3fl7]] - hEPHR A2 ectodomain<BR /> | ||
**[[2k9y]], [[2e8n]] - hEPHR A2 transmembrane domain – NMR<BR /> | **[[2k9y]], [[2e8n]] - hEPHR A2 transmembrane domain – NMR<BR /> | ||
| - | **[[1mqb]], [[4p2k]], [[4pdo]], [[4trl]] - hEPHR A2 kinase domain<BR /> | + | **[[1mqb]], [[4p2k]], [[4pdo]], [[4trl]], [[5ek7]], [[5i9u]] - hEPHR A2 kinase domain<BR /> |
*''Ephrin A2 receptor binary complex''<br /> | *''Ephrin A2 receptor binary complex''<br /> | ||
| Line 41: | Line 41: | ||
**[[3mbw]] - hEPHR A2 LBD + carbohydrate-recognition domain + ephrin A1<br /> | **[[3mbw]] - hEPHR A2 LBD + carbohydrate-recognition domain + ephrin A1<br /> | ||
**[[2kso]] - hEPHR A2 SAM + SHIP2<br /> | **[[2kso]] - hEPHR A2 SAM + SHIP2<br /> | ||
| + | **[[5i9v]], [[5i9w]] - hEPHR A2 kinase domain + inhibitor<br /> | ||
| + | **[[5i9x]], [[5i9y]], [[5i9z]], [[5ia0]], [[5ia1]], [[5ia2]], [[5ia3]], [[5ia4]], [[5ia5]] - hEPHR A2 kinase domain + kinase drug<br /> | ||
| + | |||
*Ephrin A3 receptor | *Ephrin A3 receptor | ||
| + | |||
**[[2qo2]], [[2qob]], [[2gsf]] - hEPHR A3 kinase domain<BR /> | **[[2qo2]], [[2qob]], [[2gsf]] - hEPHR A3 kinase domain<BR /> | ||
**[[2qok]], [[2qol]], [[2qon]], [[2qoo]], [[2qod]], [[2qof]], [[2qoi]] - hEPHR A3 kinase domain (mutant) <BR /> | **[[2qok]], [[2qol]], [[2qon]], [[2qoo]], [[2qod]], [[2qof]], [[2qoi]] - hEPHR A3 kinase domain (mutant) <BR /> | ||
**[[3fxx]], [[3fy2]] – hEPHR A3 kinase domain + peptide substrate<BR /> | **[[3fxx]], [[3fy2]] – hEPHR A3 kinase domain + peptide substrate<BR /> | ||
**[[2qoq]], [[2qo7]], [[2qo9]], [[2qoc]] - hEPHR A3 kinase domain + AMP-PNP<BR /> | **[[2qoq]], [[2qo7]], [[2qo9]], [[2qoc]] - hEPHR A3 kinase domain + AMP-PNP<BR /> | ||
| - | **[[3dzq]], [[4gk2]], [[4gk3]], [[4gk4]], [[4p5q]], [[4p5z]] - hEPHR A3 kinase domain + inhibitor<br /> | + | **[[3dzq]], [[4gk2]], [[4gk3]], [[4gk4]], [[4p5q]], [[4p5z]], [[4p4c]], [[4twn]], [[4two]] - hEPHR A3 kinase domain + inhibitor<br /> |
**[[4g2f]] - hEPHR A3 kinase domain (mutant) + inhibitor<br /> | **[[4g2f]] - hEPHR A3 kinase domain (mutant) + inhibitor<br /> | ||
| + | **[[4l0p]] - hEPHR A3 LBD + Ephrin-A5<br /> | ||
| + | |||
*Ephrin A4 receptor | *Ephrin A4 receptor | ||
| + | |||
**[[2wo1]], [[3ckh]] - hEPHR A4 LBD<BR /> | **[[2wo1]], [[3ckh]] - hEPHR A4 LBD<BR /> | ||
**[[4bk4]], [[4m4p]] - hEPHR A4 ectodomain<br /> | **[[4bk4]], [[4m4p]] - hEPHR A4 ectodomain<br /> | ||
| Line 58: | Line 65: | ||
**[[2wo3]] - hEPHR A4 LBD + ephrin A2 receptor-binding domain<BR /> | **[[2wo3]] - hEPHR A4 LBD + ephrin A2 receptor-binding domain<BR /> | ||
| - | **[[4w4z]], [[4w50]] - hEPHR A4 LBD (mutant) + peptide<br /> | + | **[[4w4z]], [[4w50]], [[5jr2]] - hEPHR A4 LBD (mutant) + peptide<br /> |
**[[2wo2]], [[3gxu]] - hEPHR A4 LBD + ephrin B2 receptor-binding domain<br /> | **[[2wo2]], [[3gxu]] - hEPHR A4 LBD + ephrin B2 receptor-binding domain<br /> | ||
**[[4bk5]], [[4bka]], [[4m4r]] - hEPHR A4 ectodomain + ephrin A5 LBD<br /> | **[[4bk5]], [[4bka]], [[4m4r]] - hEPHR A4 ectodomain + ephrin A5 LBD<br /> | ||
| Line 64: | Line 71: | ||
**[[2xyu]] – mEPHR A4 kinase domain + inhibitor<br /> | **[[2xyu]] – mEPHR A4 kinase domain + inhibitor<br /> | ||
**[[2y6o]] – mEPHR A4 kinase domain + cancer drug<br /> | **[[2y6o]] – mEPHR A4 kinase domain + cancer drug<br /> | ||
| + | |||
*Ephrin A5 receptor | *Ephrin A5 receptor | ||
| + | |||
**[[2r2p]] - hEPHR A5 kinase domain<BR /> | **[[2r2p]] - hEPHR A5 kinase domain<BR /> | ||
**[[1shx]] - mEPHR A5 <br /> | **[[1shx]] - mEPHR A5 <br /> | ||
| Line 73: | Line 82: | ||
**[[2rei]] - hEPHR A7 kinase domain<BR /> | **[[2rei]] - hEPHR A7 kinase domain<BR /> | ||
**[[3dko]] – hEPHR A7 kinase domain + inhibitor | **[[3dko]] – hEPHR A7 kinase domain + inhibitor | ||
| + | |||
*Ephrin A8 receptor | *Ephrin A8 receptor | ||
| + | |||
**[[3kul]] - hEPHR A8 kinase domain<BR /> | **[[3kul]] - hEPHR A8 kinase domain<BR /> | ||
**[[1x5l]] – hEPHR A8 fn3 domain – NMR<BR /> | **[[1x5l]] – hEPHR A8 fn3 domain – NMR<BR /> | ||
**[[1ucv]] - hEPHR A8 SAM – NMR<BR /> | **[[1ucv]] - hEPHR A8 SAM – NMR<BR /> | ||
| + | |||
*Ephrin B1 receptor | *Ephrin B1 receptor | ||
| + | |||
**[[2eao]] – hEPHR B1 SAM – NMR<BR /> | **[[2eao]] – hEPHR B1 SAM – NMR<BR /> | ||
**[[2djs]] - hEPHR B1 fn3 domain – NMR<BR /> | **[[2djs]] - hEPHR B1 fn3 domain – NMR<BR /> | ||
**[[3zfx]] - hEPHR B1 kinase domain<br /> | **[[3zfx]] - hEPHR B1 kinase domain<br /> | ||
| + | |||
*Ephrin B2 receptor | *Ephrin B2 receptor | ||
| + | |||
**[[3etp]] – hEPHR B2<BR /> | **[[3etp]] – hEPHR B2<BR /> | ||
**[[1b4f]] - hEPHR B2 SAM<br /> | **[[1b4f]] - hEPHR B2 SAM<br /> | ||
| Line 87: | Line 102: | ||
**[[1iko]] - mEPHR B2 ectodomain<br /> | **[[1iko]] - mEPHR B2 ectodomain<br /> | ||
**[[2i85]] - hEPHR B2 ectodomain<br /> | **[[2i85]] - hEPHR B2 ectodomain<br /> | ||
| + | **[[3zfm]] - hEPHR B2 kinase domain<br /> | ||
**[[1sgg]] - mEPHR B2 SAM – chicken - NMR<BR /> | **[[1sgg]] - mEPHR B2 SAM – chicken - NMR<BR /> | ||
| Line 98: | Line 114: | ||
*Ephrin B3 receptor | *Ephrin B3 receptor | ||
| + | |||
**[[3p1i]] – hEPHR B3 LBD<BR /> | **[[3p1i]] – hEPHR B3 LBD<BR /> | ||
**[[3zfy]] - hEPHR B3 kinase domain<br /> | **[[3zfy]] - hEPHR B3 kinase domain<br /> | ||
| + | **[[5l6o]], [[5l6p]] - hEPHR B3 kinase domain (mutant) + inhibitor<br /> | ||
| + | |||
*Ephrin B4 receptor | *Ephrin B4 receptor | ||
| + | |||
**[[2qkq]] – hEPHR B4 SAM<BR /> | **[[2qkq]] – hEPHR B4 SAM<BR /> | ||
**[[2e7h]] – hEPHR B4 fn3 domain - NMR<BR /> | **[[2e7h]] – hEPHR B4 fn3 domain - NMR<BR /> | ||
Revision as of 09:44, 1 May 2017
| |||||||||||
3D Structures of ephrin receptors
Updated on 01-May-2017
References
- ↑ Pitulescu ME, Adams RH. Eph/ephrin molecules--a hub for signaling and endocytosis. Genes Dev. 2010 Nov 15;24(22):2480-92. doi: 10.1101/gad.1973910. PMID:21078817 doi:http://dx.doi.org/10.1101/gad.1973910
- ↑ Genander M, Frisen J. Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol. 2010 Oct;22(5):611-6. doi: 10.1016/j.ceb.2010.08.005. PMID:20810264 doi:http://dx.doi.org/10.1016/j.ceb.2010.08.005
- ↑ Davis TL, Walker JR, Allali-Hassani A, Parker SA, Turk BE, Dhe-Paganon S. Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases. FEBS J. 2009 Aug;276(16):4395-404. PMID:19678838 doi:http://dx.doi.org/10.1111/j.1742-4658.2009.07147.x
